Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Unknown 5Completed 4Not yet recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Classical hematology 2Tumor-Agnostic 1

Conditions

Neoplasms 2Non-hematological Malignancies 1Anemia, Iron-Deficiency 1Anemia 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × iron isomaltoside 1000 × Clear all
NCT04318405 2023-07-19

Real-CHOICE

Pierre Fabre Pharma AG

Completed
327 enrolled
Classical hematology

Anemia, Iron-Deficiency

NCT01145638 2015-12-03

A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Pharmacosmos A/S

Phase 3 Completed
350 enrolled 9 charts
Tumor-Agnostic

Neoplasms

NCT01213979 2013-06-27

PK-CIA-04

Pharmacosmos A/S

Phase 1 Completed
16 enrolled

Non-hematological Malignancies

NCT01280240 2013-06-04

PK-CIA-06

Pharmacosmos A/S

Phase 1 Completed
11 enrolled
Classical hematology

Anemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡